Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel DNA synthesis method based on enzymes that is faster, cleaner, and more accurate than existing methods.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/22 | $68,000,000 | Series A |
Altitude Life Science Ventures Blue Water Life Science Fund Carbon Silicon Ventures Codon Capital Fifty Years Fiscus Ventures Horizons Ventures Humboldt Fund Mubadala Capital Northpond Ventures  Peak6 Investments RA Capital Management | undisclosed |
